Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Rimonabant to Reduce Alcohol ConsumptionCompleted
NCT00075205Phase 2Updated Jul 2, 2017
Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Healthy · Alcohol Drinking
United States
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial MetastasesTerminated
NCT01934894Phase 2Updated Jul 2, 2017
Sponsor: SCRI Development Innovations, LLC
Metastatic Breast Cancer With Intracranial Metastases
United States
Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis PatientsCompleted
NCT01061736Phase 2, Phase 3Updated Jun 28, 2017
Sponsor: Sanofi
Rheumatoid Arthritis
United States, Argentina, Australia, Austria, Belarus +31 more
Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and TaiwanCompleted
NCT02289963Phase 3Updated Jun 26, 2017
Sponsor: Sanofi
Hypercholesterolemia
South Korea, Taiwan
An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled AsthmaCompleted
NCT01854047Phase 2Updated Jun 26, 2017
Sponsor: Sanofi
Asthma
United States, Argentina, Australia, Chile, France +11 more
To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)Completed
NCT01768572Phase 3Updated Jun 26, 2017
Sponsor: Sanofi
Rheumatoid Arthritis
United States, Argentina, Belgium, Brazil, Czechia +14 more
An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of SinusitisCompleted
NCT01920893Phase 2Updated Jun 26, 2017
Sponsor: Sanofi
Nasal Polyps
United States, Belgium, Spain, Sweden
EUpertstrain 4 Study of Bordetella Pertussis IsolatesCompleted
NCT03197597N/AUpdated Jun 23, 2017
Sponsor: University of Turku
Bordetella Pertussis, Whooping Cough
Finland
Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing SpondylitisTerminated
NCT01118728Phase 2Updated Jun 21, 2017
Sponsor: Sanofi
Ankylosing Spondylitis
United States, Australia, Austria, Belgium, Canada +7 more
Phase II Study to Analyze Sarilumab in Non-Infectious UveitisCompleted
NCT01900431Phase 2Updated Jun 20, 2017
Sponsor: Sanofi
Uveitis
United States, Czechia, France, Italy, Spain +1 more
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)Completed
NCT02121210Phase 3Updated Jun 20, 2017
Sponsor: Sanofi
Rheumatoid Arthritis
United States, Chile, Czechia, Estonia, Hungary +2 more
To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid ArthritisCompleted
NCT02057250Phase 3Updated Jun 20, 2017
Sponsor: Sanofi
RA
United States, Chile, Mexico, Poland, Russia +1 more
The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis PatientsUnknown
NCT03193086N/AUpdated Jun 20, 2017
Sponsor: Glostrup University Hospital, Copenhagen
Multiple Sclerosis
Denmark
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck CancerTerminated
NCT00591149Phase 2Updated Jun 14, 2017
Sponsor: University of Kansas Medical Center
Head and Neck Cancer · Carcinoma, Squamous
United States
The Dual Antiplatelet Therapy Study (DAPT Study)Completed
NCT00977938Phase 4Updated Jun 9, 2017
Sponsor: Baim Institute for Clinical Research
Coronary Artery Disease
United States, Australia, Czechia, France, Germany +5 more
Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal CancerWithdrawn
NCT00408772Phase 2Updated Jun 9, 2017
Sponsor: University of California, Davis
Colorectal Cancer · Metastatic Cancer
United States
Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic AsthmaCompleted
NCT01312961Phase 2Updated Jun 8, 2017
Sponsor: Sanofi
Asthma
United States
Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.Completed
NCT00798005Phase 2Updated Jun 8, 2017
Sponsor: Sanofi
Severe Peripheral Artery Occlusive Disease
United States
Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 RegimenCompleted
NCT01457885Phase 2Updated Jun 2, 2017
Sponsor: University of Michigan Rogel Cancer Center
Acute Myeloblastic Leukemia
United States, Canada
Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate CancerCompleted
NCT00225420Phase 1, Phase 2Updated Jun 1, 2017
Sponsor: UNC Lineberger Comprehensive Cancer Center
Prostate Cancer
United States
Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaTerminated
NCT00708721Phase 1, Phase 2Updated Jun 1, 2017
Sponsor: University of Utah
Cancer · Chronic Myelomonocytic Leukemia
United States
Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian CancerCompleted
NCT01462149Phase 2Updated May 31, 2017
Sponsor: Asan Medical Center
Advanced Ovarian Cancer
South Korea
Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years OldCompleted
NCT02089347Phase 3Updated May 30, 2017
Sponsor: Sanofi Pasteur, a Sanofi Company
Tetanus · Diphtheria · Pertussis
Japan
Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung CancerCompleted
NCT01438307Phase 2Updated May 24, 2017
Sponsor: University of Alabama at Birmingham
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
United States
Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin GlargineCompleted
NCT01089569NAUpdated May 23, 2017
Sponsor: HealthPartners Institute
Type 2 Diabetes
United States

Previous page Next page